Sai Parenteral's IPO Receives Lackluster Response on First Day, Fails to Meet Subscribed Target

Sai Parenteral's IPO Receives Muted Response from Investors

Overview The initial public offering (IPO) of Sai Parenteral's, a diversified pharmaceutical formulations company, opened for subscription on March 23, 2026, and received a muted response from investors. The issue was subscribed just 0.05 times by the end of the day, with 3.35 lakh shares bid for against 72.99 lakh shares on offer, according to exchange data.

Subscription Details The retail portion was subscribed 0.03 times, while the non-institutional investor (NII) portion was subscribed 0.15 times. The qualified institutional buyer (QIB) portion has not yet opened for bidding. Prior to the issue opening, the company raised ₹122.6 crore from anchor investors.

IPO Details The IPO is a combination of a fresh issue of 0.73 crore shares aggregating to ₹285 crore and an offer for sale of 0.32 crore shares aggregating to ₹123.79 crore. The offer is being made through the book-building process, with not more than 50% of the net offer allocated to QIBs, while not more than 15% and 35% of the net offer reserved for NIIs and retail individual investors, respectively.

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

Utilisation of Proceeds The company plans to utilise the proceeds from the fresh issue, with ₹111 crore earmarked for capacity expansion and upgradation of manufacturing facilities, ₹18 crore for the establishment of a new R&D centre, and ₹14.30 crore for debt repayment.

Listing and Allotment The allotment status for the Sai Parenteral's IPO is slated to be finalised on March 30, with the tentative listing date set for April 2. The grey market premium (GMP) of Sai Parenteral's is showing nil, indicating that the stock might list at the same price as the IPO price.

Company Overview Sai Parenteral's is a diversified pharmaceutical formulations player with capabilities in research, development, and manufacturing. It operates in the branded generic formulations segment and also provides contract development and manufacturing organisation (CDMO) products and services for domestic and international markets.